Antibodies, Monoclonal/metabolism; Breast Neoplasms/drug therapy/immunology; Doxorubicin/administration & dosage; Drug Carriers; Humans; Laminin/immunology; Liposomes; Receptors, Immunologic/immunology/metabolism; Receptors, Laminin; Tumor Cells, Cultured
Abstract :
[en] The tumor cell laminin receptor is a cell-surface protein that binds laminin with high affinity (Kd = 1.0 nM). The putative ligand-binding domain of the laminin receptor has been molecularly cloned and sequenced. In the present study, we used the predicted amino acid sequence of the laminin receptor to generate synthetic peptide antigens and produced immunoglobulin M (IgM) anti-laminin receptor monoclonal antibodies. The disulfide bond group of the IgM molecule was used to couple the antibodies to the surface of liposomes encapsulating doxorubicin. The anti-laminin receptor monoclonal antibodies coupled to the liposomes bound avidly to the surface of MDA-MB-435S (MDA-435) human breast carcinoma cells, which have high numbers of laminin receptors. These antibody-coupled liposomes exhibited a low degree of binding to Hs 578Bst (Hs 578) normal human breast epithelial cells, which express a low number of laminin receptors. Excess liposomes competed for the binding of unbound laminin to the tumor cell surface, and excess laminin competed for binding with the liposomes. Antibody-coupled liposomes encapsulating doxorubicin were specifically more efficient in inhibiting colony formation by MDA-435 cells in vitro than unbound doxorubicin or liposomes without anti-laminin receptor monoclonal antibodies. Unbound doxorubicin inhibited thymidine uptake by 10%-20% in both Hs 578 and MDA-435 cells, whereas the antibody-coupled liposomes encapsulating doxorubicin inhibited thymidine uptake by 90% in MDA-435 cells but only 15% in Hs 578 cells. Thus, use of anti-laminin receptor monoclonal antibodies coupled with liposomes encapsulating doxorubicin represents a new strategy for selective targeting of doxorubicin to carcinoma cells with exposed laminin receptors.
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire - GIGA-R : Labo de recherche sur les métastases
Sobel, M. E.
Abraham, K.
Daddona, P. E.
Liotta, L. A.
Language :
English
Title :
Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro.
Publication date :
1989
Journal title :
Journal of the National Cancer Institute
ISSN :
0027-8874
eISSN :
1460-2105
Publisher :
Oxford University Press, Cary, United States - North Carolina
Gregoriadis G: The liposome drug-carrier concept: Its development and future. In Liposomes in Biological Systems (Gregoriadis G, Allison. AC, eds). New York: Wiley, 1980, pp 25-86
Weinstein JN: Liposomes as drug carriers in cancer therapy. Cancer Treat Rep 68:127-135, 1984
Alving CR: Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 22:407-424, 1983
Wewer UM, Liotta LA, Jaye M, ET AL: Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. Proc Natl Acad Sci USA 83:7137-7141,1986
Yow H, Wong JM, Chen HS, ET AL: Increased mRNA expression of a laminin-binding protein in human colon carcinoma: Complete sequence of a full-length cDNA encoding protein. Proc Natl Acad Sci USA 85:6394-6398, 1988 Vol. 81, No. 23, December 6, 1989
Wewer UM, Taraboletti G, Sobel ME, ET AL: Role of laminin receptor in tumor cell migration. Cancer Res 47:5691-5698, 1987
Rahman A, Fumagalli A, Goodman A, ET AL: Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 11:45-55, 1984
Panneerselvam M, Welt S, Old LJ, ET AL: A molecular mechanism of complement resistance of human melanoma cells. J Immunol 136:2534-2541, 1986
Pinto AL, Lippard SJ: Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780:167-180, 1985
Leserman LD, Barbet J, Kourilsky F, ET AL: Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602-604, 1980
Leserman LD, Machy P, Barbet J: Cell specific drug transfer from liposomes bearing monoclonal antibodies. Nature 293:226-228, 1981
Huang A, Kennel SJ, Huang L: Interaction of immunoliposomes with target cells. J Biol Chem 258:14034-14040, 1983
Bragman KS, Heath TD, Papahadjopoulos D: Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim Biophys Acta 730:187-195, 1983
Terranova VP, Rao CN, Kalebic T, ET AL: Laminin receptor on human breast carcinoma cells. Proc Natl Acad Sci USA 80:444-448, 1983
Liotta LA, Hand PM, Rao CN, ET AL: Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites. Exp Cell Res 156:117-126, 1985
Middleman E, Luce J, Frei E III: Clinical trials with Adriamycin. Cancer 28:844-850, 1971
Rahman A, Roh JK, Treat J, ET AL: Clinical pharmacology of liposome encapsulated doxorubicin (LED) in phase I trials. Proc ASCO 6:31, 1987
Treat J, Forst D, Woolley PV, ET AL: Liposome encapsulated doxorubicin (LED): A phase II study in measurable recurrent breast cancer patients. Proc ASCO 7:41, 1988
Lopez-Berestein G, Fainstein V, Hopfer R, ET AL: Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer A preliminary study. J Infect Dis 151:704-710, 1985